Donanemab + 2-Pyrazinecarboxamide, N-[3-[(4aR,7aS)-2-amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl]-5-methoxy- for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Dec 2017: Trial registered, NCT03367403
  2. 18 Dec 2017: Trial started, NCT03367403

The trials

NCT03367403: A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

State
Completed
Phase
Phase 2
People
272 taking part
Started
18 Dec 2017
Primary completion
4 Dec 2020
Arms
Donanemab in Combination With LY3202626 (Donanemab-C)
Results
Posted on the registry
  1. 8 Dec 2017: Trial registered
  2. 18 Dec 2017: Trial started
  3. 21 Sep 2021: Trial completed
  4. 15 Feb 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.